معرفی
Professor Mibel Aguilar is a leading academic at Monash University’s Monash Biomedicine Discovery Institute, affiliated with the Department of Biochemistry & Molecular Biology. Her research focuses on peptide-based drug design, membrane biology, and biomaterials development, with applications in cardiovascular disease treatment, antimicrobial peptide mechanisms, and stem cell-based tissue regeneration. She has led over 50 projects, including the ARC Training Centre for Cell and Tissue Engineering Technologies (2021–2027), and contributed to the Sustainable Development Goals through her work on novel therapies and biomaterials.
Education: While specific academic qualifications are not detailed, her role as a Professor indicates advanced degrees (e.g., PhD) in Biochemistry or a related field.
Research Interests: Her group explores peptide-membrane interactions for drug design, developing biomaterials for regenerative medicine, and understanding membrane protein dynamics. Key areas include AT2 receptor agonists for cardiac fibrosis, β-peptide nanomaterials, and antimicrobial peptide mechanisms against bacterial membranes. Her work bridges basic science and translational medicine, aiming to rationalize peptide/protein-based therapeutics.
Publications: Her recent work includes studies on lipidated peptide nanomaterials (2024), AT2 receptor therapies (2024), and membrane lipid dynamics (2024). Articles highlight advancements in biomaterials, cardiovascular therapeutics, and microbial membrane interactions.
Grants & Collaborations: She leads and collaborates on projects funded by the Australian Research Council, industry partners (e.g., PolVax Pty Ltd), and organizations like the Ian Potter Foundation. Notable collaborations include work on pathogenic membranes and antimicrobial resistance (Monash Antimicrobial Resistance Group).
Labs & Teams: Her lab integrates biophysics, chemistry, and biology to create innovative biomaterials and therapies. She is a core member of the ARC Training Centre, fostering industry-academia partnerships in cell and tissue engineering.
